Total 208, page 5/11
No. | Organization | Therapeutic Area | Product Type | Title |
---|---|---|---|---|
78 | LifeArc | Orthopedics | Small molecule | Matriptase_OA and Inflammatory diseases |
77 | Lead Discovery Center | Metabolic disease | Small molecule | GPR81 antagonist to treat Metabolic Diseases |
76 | Lead Discovery Center | Immunology, Oncology | Small molecule | BH4_Cancer, Autoimmune diseases |
75 | Lead Discovery Center | Oncology | Antibody | GDF-15_Cancer, Cachexia |
74 | Lead Discovery Center | Inflammatory disease | Small molecule | NETosis_Sepsis, Autoimmune disorder |
73 | Lead Discovery Center | Immunology | Small molecule | GLUT 1, 3_Cancer, Autoimmune disorder |
72 | Imperial College London | Neurology, CNS disease | Gene therapy | Novel treatment for Huntington’s Disease |
71 | Imperial College London | Immunology | Peptide | STp, Protease Resistant Peptide from Lactobacillus Plantarum |
70 | Fraunhofer IZI | Immunology, CNS disease | Cell therapy | Exosomes_AD, RA |
69 | Fraunhofer IZI | Immunology | Small molecule | Mephrin inhibitor_Fibrosis, AKI |
68 | Fraunhofer IZI | Infectious disease | Small molecule | Periodontitis_Infection |
67 | CRUK | Oncology | Small molecule | Enhancing Antibody Agonism_Cancer |
66 | CRUK | Oncology | Antibody | Anti-integrin αvβ6 antibody_Cancer, Fibrosis |
65 | CRUK | Oncology | Small molecule | IKK-α selective compound_Prostate Cancer |
64 | CNRS | Neurology, CNS disease | Small molecule | DYRK1A Protein inhibitor_ Down's syndrome, AD |
63 | CNRS | Neurology, CNS disease | Peptide | Mutant huntingtin protein_Huntington's diseases |
62 | CD3 | Immunology | Small molecule | STING - cGAS_Autoimmune disorder |
61 | CD3 | Oncology | Small molecule | LEDGF PWWP chromatin tethering_Cancer |
60 | CD3 | Oncology | Small molecule | MALT1 inhibitor_Solid and Hematological tumor |
59 | CD3 | Oncology | Small molecule | OXPHOS, DHODH inhibitor_AML |